Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) exhibits high clinical and biological heterogeneity, which complicates the development of one-size-fits-all therapeutic strategies. Standard trial designs can mask subgroup-specific effects, highlighting the need to move towards precision neurology entailing multisystem genomics, biomarkers, and artificial intelligence (AI) integrative signals. The aim of the study is to critically synthesize and evaluate emerging strategies for drug optimization and individual therapeutic algorithms informed by genomic architecture, pharmacogenomics (PGx), and polygenic risk scores (PRS) with the opinion to resolve the controversy and unanswered question. Amplify the convergence into amyloid processing, lipid metabolism, and innate immunity seen from monogenic mutations and over 80 GWAS risk loci. Genotyping of CYP2D6 and CYP2C19 variants permits pharmacogenomic stratifications for the optimization of cholinesterase inhibitor and psychotropic dosing, thereby reducing adverse events. Variants of the alleles APOE ε4 and immune-related factors (e.g., FCGR3A) are significant in predicting the effects of ARIA associated with amyloid on anti-amyloid immunotherapy outcomes. PRS and deep phenotyping (including digital and fluid-based biomarkers) allow for the identification of unique biological endotypes (e.g., tau-dominant vs. vascular-inflammatory) that improve clinical trial enrichment and prognostication. This framework delineates molecular endotypes and translates CYP2D6 or APOE stratification into drug dosing and ARIA risk predictions. These biomarker-driven strategies shift AD management from a passive, reactive therapeutic scheme to an active, personalized one. Utilization of high-dimensional data streams via AI-driven learning health systems converts AD management from a reactive, symptom-based model to that which is proactive and hallmark biomarker-driven precision.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chakraborty, W., & Roy, K. K. (2026). Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention. Molecular neurobiology. https://doi.org/10.1007/s12035-026-06313-w

Vancouver

Chakraborty W, Roy KK. Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention. Molecular neurobiology. 2026. doi:10.1007/s12035-026-06313-w. PMID: 43018845.

BibTeX

@article{chakraborty2026-43018845,
  author  = {Chakraborty, W. and Roy, K. K.},
  title   = {{Precision Neurology in Alzheimer's Disease: Genomics to Drug Optimization for Effective Therapeutic Intervention}},
  journal = {Molecular neurobiology},
  year    = {2026},
  doi     = {10.1007/s12035-026-06313-w},
  pmid    = {43018845},
  url     = {https://doi.org/10.1007/s12035-026-06313-w}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 0 of 2. 25 of the 58 points it could be judged on, which is 43 of 100. Total 43 of 100.25 of the 58 points we could judge = 43 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Molecular neurobiology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 43018845)
Free to read 0 / 2 Behind a paywall — scores zero
Points 25 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100.
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “neurology”

3 studies in the library carry the topic tag “neurology”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →